114 completed, 30 recruiting, 26 unknown, 16 active not recruiting. 89 Phase 2, 77 Phase 3, 23 Phase 4, 21 Phase 1, 13 Not applicable.
Follow Mercaptopurine: new trials by email Literature Review of Mercaptopurine trials Research Report on Mercaptopurine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial Inotuzumab Ozogamicin (IO), Venetoclax, Blinatumomab - Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 32 | 2026-06-12 | 2026-06-11 |
| Immunosuppressant Discontinuation in Elderly Patients With Ulcerative Colitis And Long-term Remission Discontinuation of thiopurines. - Ulcerative Colitis (UC) | Phase 4 | Not yet recruiting | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | 304 | 2026-05-01 | 2026-04-15 |
| ALL Backbone in AYAs Blinatumomab, Oncaspar, Cyclophosphamide - Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 67 | 2026-04-03 | 2026-08-17 |
| Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis Prednisone, Vincristine, Mercaptopurine - Langerhans Cell Histiocytosis (LCH) | Not applicable | Recruiting | West China Second University Hospital | 120 | 2026-02-13 | 2026-02-24 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-27 |
| Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma Dexamethasone, Vincristine, Inotuzumab - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 128 | 2025-01-23 | 2026-07-16 |
| Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 100 | 2024-12-27 | 2026-08-10 |
| A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home Biospecimen Collection, Compliance Monitoring, Health Promotion and Education - Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia | Not applicable | Suspended | Children's Oncology Group | 64 | 2024-12-04 | 2026-10-05 |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-09 | 2024-05-17 | |
| A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients Hydroxyurea, Hydroxycarbamide, Valproic acid, 6-Mercaptopurine (6-MP) - Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult | Phase 1 / Phase 2 | Recruiting | Haukeland University Hospital | 48 | 2024-05-23 | 2025-06-29 |
| Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL Vincristine, Cyclophosphamide, Dexamethasone - Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 53 | 2024-04-02 | 2025-12-17 |
| Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate, Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate, Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate - Lymphoblastic Leukemia in Children | Phase 2 | Recruiting | Hee Young Ju | 116 | 2024-03-05 | 2026-07-29 |
| Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL Vincristine, Dexamethasone, Imatinib - Lymphoblastic Leukemia, Philadelphia-Positive ALL | Not yet recruiting | PETHEMA Foundation | 150 | 2023-12-25 | 2023-12-19 | |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Dexamethasone, Mitoxantrone, PEG asparaginase - Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Tanja Andrea Gruber | 90 | 2023-11-03 | 2026-06-03 |
| Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil Prednisone, Vincristin, Daunorubicin - Acute Lymphoid Leukemia, Minimal Residual Disease | Recruiting | Instituto do Cancer do Estado de São Paulo | 180 | 2023-09-05 | 2025-05-07 |
Showing 20 of 211. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (109) · Leukemia (66) · Burkitt Lymphoma (27) · Lymphoma (18) · Leukemia, Biphenotypic, Acute (14) · Crohn Disease (11) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (9) · Leukemia, Promyelocytic, Acute (7) · Colitis, Ulcerative (6) · Neoplasm, Residual (6) · Inflammatory Bowel Diseases (5) · Leukemia, Myeloid, Acute (5) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (5) · Down Syndrome (4) · Dendritic Cell Sarcoma, Interdigitating (3)
Children's Oncology Group (30) · National Cancer Institute (NCI) (21) · St. Jude Children's Research Hospital (17) · M.D. Anderson Cancer Center (11) · PETHEMA Foundation (7) · Goethe University (6) · Institute of Hematology & Blood Diseases Hospital, China (5) · SWOG Cancer Research Network (5) · Alliance for Clinical Trials in Oncology (4) · Dana-Farber Cancer Institute (4) · Gruppo Italiano Malattie EMatologiche dell'Adulto (4) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Johann Wolfgang Goethe University Hospital (3) · Sun Yat-sen University (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2)
United States (115) · Canada (43) · Australia (34) · Germany (25) · Puerto Rico (24) · Switzerland (22) · China (19) · Netherlands (16) · France (15) · Italy (15) · New Zealand (14) · Israel (12) · Austria (10) · Belgium (10) · Czechia (10)
Sima Jeha, MD (6) · Dieter Hoelzer, MD,PhD (4) · Dieter Hoelzer, MD, PhD (3) · Elias Jabbour (3) · Smita Bhatia (3) · Wendy Stock, MD (3) · Allen Yeoh, MBBS (2) · Anne L Angiolillo (2) · Fumihiko Hayakawa, MD (2) · Ian Trevor Magrath, MD, FRCP, FRCPath (2) · Ibrahim Aldoss (2) · Julio C. Barredo, MD (2) · Kjeld Schmiegelow, M.D. (2) · Kjeld Schmiegelow, Professor (2)
PMID 41671463, PMID 39121442, PMID 37890117, PMID 23007406, PMID 24970932, PMID 33242441, PMID 34048072, PMID 35622074, PMID 38446568, PMID 40908865, PMID 16105981, PMID 16421426, PMID 19144982, PMID 19433688, PMID 19546402, PMID 20154213, PMID 21719599, PMID 22442346, PMID 22493293, PMID 23024237, PMID 23233662, PMID 24344215, PMID 26590194, PMID 26888258, PMID 26913693, PMID 27561722, PMID 28751559, PMID 29148893, PMID 29284596, PMID 30138085, PMID 31188727, PMID 31601692, PMID 31612640, PMID 32552472, PMID 32589970, PMID 33152759, PMID 33496745, PMID 35271306, PMID 36603187, PMID 37021527, PMID 39316653, PMID 40013523, PMID 40315406, PMID 42085640, PMID 42477805, PMID 10627444, PMID 12111109, PMID 12153596, PMID 12239143, PMID 12694250
U10CA098543 (16), U10CA180886 (15), U10CA031946 (4), U10CA032102 (4), 2017 (3), P30CA016672 (3), U10CA180821 (3), U10CA180888 (3), 2009 (2), F32CA141762 (2), P30CA033572 (2), R37CA036401 (2), U10CA021115 (2), U10CA095861 (2), UG1CA189955 (2)